ConductScience.org, home

Trial · NCT01524926

CREATE: Cross-tumoral Phase 2 With Crizotinib

NCT01524926, Phase 2, Completed, European Organisation for Research and Treatment of Cancer - EORTC

3 sourcestrials-2026-11-12-0.5.0

Download JSON
Cite this record

ConductScience Library. CREATE: Cross-tumoral Phase 2 With Crizotinib. Trials, record NCT01524926. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01524926

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title
CREATE: Cross-tumoral Phase 2 With Crizotinib
NCT number
NCT01524926
Status
Completed
Phases
Phase 2
Enrollment
582 participants, estimated
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Conditions
Locally Advanced and/or Metastatic Anaplastic Large Cell Lymphoma, Locally Advanced and/or Metastatic Inflammatory Myofibroblastic Tumor, Locally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1, Locally Advanced and/or Metastatic Alveolar Soft Part Sarcoma, Locally Advanced and/or Metastatic Clear Cell Sarcoma, Locally Advanced and/or Metastatic Alveolar Rhabdomyosarcoma
Interventions
Crizotinib (PF-02341066)
First posted
2012-02-02
Last updated
2023-12-11
Other registries' IDs
eudract:2011-001988-52

Source ClinicalTrials.gov

Registered outcomes7

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

ListOutcomeTime frameDescription
PrimaryAntitumor activity of crizotinibTo study the antitumor activity of crizotinib across predefined tumor types in patients whose tumors are harboring specific alterations in ALK and/or MET
SecondarySafety (reporting of adverse events according to CTCAE v4.0)
SecondaryProgression free survival
SecondaryDisease control rate
SecondaryOverall survival
SecondaryDuration of response
SecondaryCorrelative research endpoints

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers5

The papers the trial lists on ClinicalTrials.gov.

PMIDListed asSource
28950372DERIVEDPubMed
29216400DERIVEDPubMed
29567632DERIVEDPubMed
29669701DERIVEDPubMed
34392187DERIVEDPubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov
2026-11-12
ClinicalTrials.gov
Results, from AACT
2026-03-23
AACT
NIH grant links
2026-11-13
NIH RePORTER

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01524926

GET https://conductscience.org/api/trials/v1/NCT01524926/registered